XML 73 R58.htm IDEA: XBRL DOCUMENT v3.24.1
BUSINESS ACQUISITIONS (Details)
$ in Thousands
3 Months Ended 12 Months Ended
Jan. 19, 2023
USD ($)
item
shares
Dec. 31, 2022
USD ($)
May 13, 2022
USD ($)
shares
Sep. 30, 2023
USD ($)
Jun. 30, 2022
USD ($)
Dec. 31, 2023
USD ($)
BUSINESS ACQUISITIONS            
Number of novel food applications | item 1,276          
Contingent consideration $ 1,138          
Goodwill           $ 0
Deferred Tax Assets, Valuation Allowance   $ 39,759       64,763
Measurement period adjustments       $ 53    
Gain on change of contingent consideration           (1,138)
GVB Biopharma            
BUSINESS ACQUISITIONS            
Debt assumed     $ 4,637      
Transaction costs     $ 1,753      
Shares issued | shares     2,193,334      
Fair value of shares issued     $ 51,653      
Increase (decrease) in inventory         $ 978  
Goodwill     44,200     33,360
Reduction to goodwill     10,840      
Deferred tax liability     627     627
Deferred Tax Assets, Valuation Allowance   434        
Valuation of property plant and equipment     $ 70      
GVB Biopharma | Sales, general, and administrative            
BUSINESS ACQUISITIONS            
Acquisition related costs   $ 1,046        
GVB Biopharma | Tradename            
BUSINESS ACQUISITIONS            
Royalty rate     1.00%      
GVB Biopharma | Off-market lease            
BUSINESS ACQUISITIONS            
Intangible assets     $ 0      
GVB Biopharma | Customer relationships            
BUSINESS ACQUISITIONS            
Historical customer annual attrition rate     20.00%      
RX Pharmatech Ltd            
BUSINESS ACQUISITIONS            
Number of novel food applications | item 1,276          
Cash consideration $ 200          
Equity consideration 503          
Target working capital, true up 286          
Contingent consideration 1,138          
Fair value of contingent consideration 2,127          
Intangible assets 1,744          
Net asset 93          
Excess purchase price $ 0          
Contingent consideration, earn out period 3 years          
Shares issued | shares 31,056          
Cash acquired $ 290          
Goodwill 0          
RX Pharmatech Ltd | Sales, general, and administrative            
BUSINESS ACQUISITIONS            
Acquisition related costs           $ 130
RX Pharmatech Ltd | Maximum            
BUSINESS ACQUISITIONS            
Contingent consideration $ 1,550